Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated endostatin + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Pegylated endostatin (PEG-ENDO) is a mono-PEGylated recombinant human form of endostatin, an endogenous protein fragment derived from type XVIII collagen. Endostatin acts as a potent inhibitor of angiogenesis by suppressing vascular endothelial growth factor A (VEGF-A) expression and interfering with multiple signaling pathways involved in endothelial cell migration and proliferation, including inhibition of matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), α5β1-integrin-mediated signaling, and Wnt/β-catenin pathways[3][5]. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. Carboplatin is an organoplatinum alkylating agent that induces DNA cross-linking, leading to apoptosis in rapidly dividing cells[2]. The combination of these three agents has been investigated for the treatment of advanced non-small cell lung cancer (NSCLC), leveraging antiangiogenic effects alongside cytotoxic chemotherapy[5].
- Other names
- PEG-ENDO + paclitaxel + carboplatin
02
Targets
MMP2 (Matrix metalloproteinase-2)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))DNAMMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on pegylated endostatin + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated endostatin + paclitaxel + carboplatin.